Galmed Pharmaceuticals (NASDAQ:GLMD) reported quarterly losses of $(0.30) per share which met the analyst consensus estimate. This is a 37.5 percent increase over losses of $(0.48) per share from the same period last year.
RBC Capital Maintains Outperform on Ivanhoe Mines, Raises Price Target to C$12
RBC Capital analyst Sam Crittenden maintains Ivanhoe Mines (TSX:IVN) with a Outperform and raises the price target from C$10 to C$12.
